Published in

Massachusetts Medical Society, New England Journal of Medicine, 13(368), p. 1199-1209, 2013

DOI: 10.1056/nejmoa1213261

Elsevier, Breast Diseases, 4(24), p. 350-352, 2013

DOI: 10.1016/j.breastdis.2013.10.034

Links

Tools

Export citation

Search in Google Scholar

Analysis of circulating tumor DNA to monitor metastatic breast cancer.

Journal article published in 2013 by Sj Dawson, Dw Tsui, Muhammed Murtaza ORCID, Heather Biggs, Om Rueda, Sf Chin, Mj Dunning ORCID, Davina Gale, Tim Forshew ORCID, N. Tokudome, Betania Mahler-Araujo, Sabrina Rajan, Sean Humphray, Jennifer Becq, David Halsall and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer.